Financial Data and Key Metrics Changes - Revenue grew 5% in Q3 to $11.12 billion, with adjusted operating income increasing 9% to $2.59 billion [5][21] - Adjusted operating margin expanded by 100 basis points to 23.3% [5][21] - Adjusted EPS increased by 10% to $5.79 per share [5][20] Business Line Data and Key Metrics Changes - **Pharma and Biotech**: Mid-single-digit growth driven by bioproduction and analytical instruments [6] - **Academic and Government**: Revenue declined in low single digits, showing modest improvement [6] - **Industrial and Applied**: Revenue grew in mid-single digits, led by electron microscopy [6] - **Diagnostics and Healthcare**: Revenue growth improved but remained down low single digits, primarily due to conditions in China [6][25] Market Data and Key Metrics Changes - North America grew low single digits, Europe and Asia-Pacific grew mid-single digits, while China declined mid-single digits [21] - Total company adjusted gross margin was 41.9%, reflecting strong productivity [21] Company Strategy and Development Direction - The growth strategy focuses on high-impact innovation, trusted partner status, and a strong commercial engine [7][10] - Recent innovations include FDA-approved diagnostic tests and new electron microscopes [8][9] - Strategic collaborations, such as with OpenAI and AstraZeneca, aim to enhance product offerings and drive innovation [10][13] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating government policies and reshoring activities in the U.S. [33][34] - The company raised its full-year revenue guidance to $44.1 billion to $44.5 billion and adjusted EPS guidance to $22.60 to $22.86 [17][27] - Management remains optimistic about midterm and long-term growth prospects, expecting organic growth of 3% to 6% [54] Other Important Information - The company completed significant acquisitions, including a filtration and separation business and a sterile fill-finish site, enhancing its capabilities [14][15] - Share repurchases totaled $1 billion in Q3, bringing the total for the year to $3 billion [15][23] Q&A Session Summary Question: Market conditions and customer conversations - Management noted excitement among pharma and biotech customers regarding scientific breakthroughs and confidence in their pipelines [33][34] Question: Academic and government funding outlook - Management indicated a more stable funding environment is expected, despite the ongoing government shutdown adding some uncertainty [37][38] Question: Analytical instruments performance - Growth was driven by strong demand in electron microscopy and chromatography, with expectations for continued momentum [44] Question: Diagnostics in China - Management acknowledged weak conditions in China but noted a modest improvement relative to the previous quarter [45][46] Question: Biopharma demand from small biotech - There was positive momentum in clinical research and early activities in pharma services, indicating a potential reinvestment cycle [66][67] Question: Onshoring impact on capacity and volumes - Management discussed incremental demand from new facilities and equipment, but noted that overall drug volumes would remain stable [73][74]

Financial Data and Key Metrics Changes - Revenue grew 5% in Q3 2025 to $11.12 billion [6][26] - Adjusted operating income increased 9% to $2.59 billion [6][27] - Adjusted operating margin expanded by 100 basis points to 23.3% [6][27] - Adjusted EPS rose 10% to $5.79 per share [6][26] Business Line Data and Key Metrics Changes - **Pharma and Biotech**: Mid single-digit growth, driven by bioproduction and analytical instruments [6][7] - **Academic and Government**: Revenue declined in low single digits, showing slight improvement [7][52] - **Industrial and Applied**: Revenue grew in mid single digits, led by electron microscopy [8][32] - **Diagnostics and Healthcare**: Revenue growth improved but remained down low single digits, primarily due to conditions in China [8][64] Market Data and Key Metrics Changes - North America grew low single digits; Europe and Asia Pacific grew mid single digits; China declined mid single digits [26][27] - Total company adjusted gross margin was 41.9%, up 10 basis points year-over-year [28] Company Strategy and Development Direction - The growth strategy focuses on high-impact innovation, trusted partner status, and a strong commercial engine [9][13] - Collaborations with OpenAI aim to enhance product offerings and operational efficiency [14][15] - Strategic partnerships, such as with AstraZeneca, are intended to drive innovation in life sciences [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating government policies and the potential for reshoring in the pharma sector [46][49] - The company raised its full-year revenue guidance to $44.1 billion to $44.5 billion and adjusted EPS guidance to $22.6 to $22.86 [22][36] Other Important Information - The company repurchased $1 billion of shares in Q3, totaling $3 billion for the year [20][30] - The integration of recent acquisitions is progressing smoothly, with positive early feedback from customers [18][19] Q&A Session Summary Question: Market conditions and customer conversations - Management noted excitement around scientific breakthroughs and confidence in customer pipelines, with a focus on reshoring and navigating government policies [46][49] Question: Academic and government funding outlook - Management indicated a more stable funding environment is expected, despite the government shutdown adding some uncertainty [53][55] Question: Analytical instruments performance - Growth was driven by strong demand in electron microscopy and chromatography, with a positive outlook for the fourth quarter [60][62] Question: Diagnostics in China - Weak conditions were noted in China, but the company remains well-positioned for long-term growth despite current pressures [64][92] Question: 2026 growth outlook - Management remains confident in a 3% to 6% organic growth range, with expectations for improved market conditions over time [68][70] Question: Clinical research business trends - The clinical research business is performing well, with strong authorization rates and innovative approaches to improve drug development efficiency [78][80] Question: Demand from small and emerging biotech - There is a positive trend in demand from small biotech firms, supported by recent M&A activity in the sector [87]

Financial Data and Key Metrics Changes - Revenue grew 5% in Q3 2025 to $11.12 billion, with adjusted operating income increasing 9% to $2.59 billion [5][21] - Adjusted operating margin expanded by 100 basis points to 23.3%, and adjusted EPS rose 10% to $5.79 per share [5][21] - Full-year revenue guidance raised to a range of $44.1 billion to $44.5 billion, with adjusted EPS guidance increased to $22.60 to $22.86 [17][27] Business Line Data and Key Metrics Changes - **Pharma and Biotech**: Mid-single-digit growth driven by bioproduction and analytical instruments [6] - **Academic and Government**: Revenue declined in low single digits, showing slight improvement from the previous quarter [6] - **Industrial and Applied**: Revenue grew in mid-single digits, led by electron microscopy [6] - **Diagnostics and Healthcare**: Revenue growth improved but remained down low single digits, primarily due to conditions in China [6][46] Market Data and Key Metrics Changes - North America grew low single digits, while Europe and Asia-Pacific both grew mid-single digits; China declined mid-single digits [20] - Adjusted gross margin was 41.9%, reflecting strong productivity [21] Company Strategy and Development Direction - The growth strategy focuses on high-impact innovation, trusted partner status, and a strong commercial engine [7][11] - Collaborations with OpenAI aim to enhance product development and operational efficiency [12][13] - Recent acquisitions, including the filtration and separation business from Solventum and a Sterile Fill Finish site from Sanofi, are expected to strengthen the company's capabilities [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating government policies and reshoring activities, which are expected to benefit the company [34][36] - The company anticipates a stable funding environment in the academic and government sectors, which may remove headwinds over time [39] - The outlook for 2026 remains positive, with expectations of 3% to 6% organic growth [50][51] Other Important Information - The company repurchased $1 billion of shares in Q3, totaling $3 billion for the year [15][22] - Free cash flow for the year is expected to be around $7 billion [30] Q&A Session Summary Question: Market conditions and customer conversations - Management noted excitement among pharma and biotech customers regarding scientific breakthroughs and confidence in their pipelines [34] Question: Academic and government funding outlook - Management indicated that while conditions were muted, there is a consensus around a relatively flat budget, which could stabilize the market [39] Question: Analytical instruments performance - Growth was driven by strong demand in electron microscopy and chromatography, with expectations for continued momentum [44][45] Question: China diagnostics market conditions - Management acknowledged weak conditions in China but noted a modest improvement relative to the prior quarter [46] Question: Demand from small and emerging biotech - There was positive momentum in clinical research business, with expectations for increased reinvestment in the market [61] Question: Onshoring impact on demand - Management highlighted that onshoring will create incremental demand for new equipment and facilities, although overall drug volumes may not change significantly [68]

Core Insights - Thermo Fisher Scientific (TMO) reported quarterly earnings of $5.79 per share, exceeding the Zacks Consensus Estimate of $5.5 per share and up from $5.28 per share a year ago [1] - The company achieved revenues of $11.12 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.99% and increasing from $10.6 billion year-over-year [3] Earnings Performance - The earnings surprise for the quarter was +5.27%, with the company having surpassed consensus EPS estimates in all four of the last quarters [2] - The previous quarter's earnings were also above expectations, with actual earnings of $5.36 compared to an expected $5.22, resulting in a surprise of +2.68% [2] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $6.48, with expected revenues of $11.78 billion, and for the current fiscal year, the estimate is $22.50 on revenues of $43.92 billion [8] - The estimate revisions trend for Thermo Fisher was unfavorable prior to the earnings release, leading to a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [7] Industry Context - Thermo Fisher operates within the Zacks Medical - Instruments industry, which is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable industry backdrop [9] - The performance of Thermo Fisher's stock may be influenced by the overall outlook for the industry, as top-ranked industries tend to outperform lower-ranked ones significantly [9]

Core Insights - Thermo Fisher exceeded analysts' expectations for third-quarter revenue and profit, driven by robust demand for its tools and technologies used in therapy development [1] Financial Performance - The company reported strong financial results, indicating a positive trend in revenue and profit growth compared to previous quarters [1] Market Demand - There is a significant increase in demand for Thermo Fisher's medical equipment, reflecting broader trends in the healthcare and biotechnology sectors [1]

Group 1 - The core point of the article is that Thermo Fisher Scientific (TMO.US) experienced a pre-market surge, rising over 3% following the announcement of its Q3 2025 net profit of $2.19 billion, which exceeded the previous year's $1.63 billion and surpassed market expectations of $1.755 billion [1] Group 2 - The company's Q3 2025 net profit was reported at $2.19 billion [1] - The previous year's net profit for the same quarter was $1.63 billion [1] - Market expectations for the Q3 2025 net profit were $1.755 billion [1]

格隆汇10月22日｜赛默飞世尔(TMO.US)2025年Q3净利润21.9亿美元，上年同期16.3亿美元，市场预期 17.55亿美元。 ...

Financial Performance - Third quarter revenue grew 5% to $11.12 billion, compared to $10.60 billion in the same quarter of 2024[6] - GAAP diluted earnings per share (EPS) was $4.27, consistent with the prior-year quarter, while adjusted EPS increased 10% to $5.79[4][8] - Organic revenue growth for the quarter was 3%[6] - GAAP operating income was $1.94 billion with an operating margin of 17.4%, compared to $1.84 billion and 17.3% in the prior year[7] - Adjusted operating income reached $2.59 billion, with an adjusted operating margin of 23.3%, up from 22.3% in the previous year[8] - Consolidated revenues for the three months ended September 27, 2025, reached $11,122 million, a 4.9% increase from $10,598 million in the same period of 2024[16] - Life Sciences Solutions segment revenues increased to $2,588 million, representing 23.3% of total revenues, compared to $2,387 million or 22.5% in the prior year[16] - Adjusted operating income for the nine months ended September 27, 2025, was $7,231 million, reflecting a margin of 22.4%, up from $6,987 million or 22.2% in 2024[23] - Net income attributable to Thermo Fisher Scientific Inc. for the nine months ended September 27, 2025, was $4,740 million, a 5.2% increase from $4,505 million in the same period of 2024[23] - Net income for the nine months ended September 27, 2025, was $4,751 million, compared to $4,514 million for the same period in 2024, reflecting an increase of 5.3%[31] Cash Flow and Assets - Free cash flow for the quarter was $1.84 billion, compared to $1.92 billion in the same quarter of 2024[15] - Free cash flow for the nine months ended September 27, 2025, was $3,319 million, down from $4,498 million in the prior year, indicating a decrease of 26.2%[31] - Total assets increased to $103,020 million as of September 27, 2025, up from $97,321 million on December 31, 2024, representing a growth of approximately 5.8%[30] - Cash and cash equivalents decreased to $1,982 million as of September 27, 2025, from $4,009 million on December 31, 2024, a decline of 50.5%[30] - The company reported a net cash used in investing activities of $4,938 million for the nine months ended September 27, 2025, compared to $5,861 million in the same period of 2024, a decrease of 15.7%[31] Liabilities - Total current liabilities rose to $14,888 million as of September 27, 2025, compared to $13,332 million at the end of 2024, marking an increase of 11.7%[30] - Long-term obligations increased to $31,857 million as of September 27, 2025, from $29,061 million at the end of 2024, representing a rise of 9.6%[30] Strategic Initiatives - The company completed acquisitions of Solventum's Filtration and Separation business and Sanofi's sterile fill-finish site, enhancing bioproduction capabilities and U.S. drug manufacturing capacity[5] - A strategic collaboration with OpenAI was established to enhance the use of artificial intelligence across operations and products[4] - The launch of innovative products included the Oncomine Dx Express Test and the Thermo Scientific Talos 12 transmission electron microscope, aimed at advancing precision medicine and structural biology research[4] Research and Development - Research and development expenses for the nine months ended September 27, 2025, were $1,041 million, consistent with 3.2% of total revenues[23] Financial Guidance and Measures - The company plans to provide updated financial guidance for 2025 during the earnings conference call[9] - The company emphasizes the importance of non-GAAP financial measures, such as organic revenue growth, to assess operational performance and financial trends[32] - The company does not provide GAAP financial measures on a forward-looking basis due to uncertainties in predicting future restructuring actions and transaction-related charges[35] - The company’s adjusted operating income and adjusted EPS metrics were not disclosed in the provided content, but these measures are used to evaluate core operating performance[33]

WILMINGTON, N.C.--(BUSINESS WIRE)--Thermo Fisher Scientific Launches Innovative Carbon Calculator to Drive Greener Clinical Trials. ...

Core Viewpoint - Thermo Fisher Scientific (TMO) is expected to report quarterly earnings of $5.50 per share, a 4.2% increase year-over-year, with revenues projected at $10.9 billion, reflecting a 2.8% year-over-year increase [1]. Earnings Estimates - The consensus EPS estimate has been revised down by 0.5% in the last 30 days, indicating a reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Forecasts - Analysts forecast 'Revenues- Laboratory Products and Biopharma Services' to reach $5.93 billion, a year-over-year increase of 3.2% [5]. - The estimate for 'Revenues- Specialty Diagnostics' is $1.16 billion, also reflecting a 3.2% year-over-year increase [5]. - 'Revenues- Life Sciences Solutions' are expected to be $2.47 billion, indicating a 3.6% year-over-year increase [5]. - 'Revenues- Analytical Instruments' are projected at $1.80 billion, showing a slight decline of 0.3% year-over-year [6]. Geographic Revenue Projections - North America revenues are expected to reach $5.74 billion, a 2.7% increase from the prior year [6]. - Asia-Pacific revenues are projected at $1.99 billion, reflecting a 3.6% year-over-year increase [6]. - Revenues from Europe are estimated to be $2.77 billion, indicating a 3.1% year-over-year increase [7]. - Revenues from other regions are expected to be $379.01 million, showing a decline of 4.5% year-over-year [7]. Stock Performance - Over the past month, Thermo Fisher shares have increased by 11.6%, outperforming the Zacks S&P 500 composite, which saw a 0.7% change [7]. - Based on its Zacks Rank 4 (Sell), TMO is expected to underperform the overall market in the upcoming period [7].